Portugal's medicines authority logged 695 suspected adverse reaction reports for GLP-1 drugs such as Mounjaro and Ozempic between January 2024 and September 2026. Nausea and vomiting lead the list; here is how to report a reaction.
Infarmed has approved SNS hospital funding for Kaftrio in patients aged 2 and over without the F508del mutation, and for Vertex's newer once-daily Alyftrek from age 6. Who qualifies, how they get it and what is still unknown.
Infarmed's monthly export suspension list, in force since 6 October, keeps every solid oral form of quetiapine in Portugal, plus 52 scarce presentations from tramadol drops and trazodone to cancer drugs and an asthma inhaler.
Infarmed refused a co-payment for Nilemdo and Nustendi and kept the rare-disease drug Evkeeza out of hospitals over price, but approved Elahere after a deal.
INFARMED's July report puts patient spending at 571.6 million euros, up 2.1 percent, and the SNS share at 1,179.3 million, up 8.3 percent. The average co-payment per pack actually fell two cents. What rose was volume, and one diabetes class accounts for a third of the increase.
Infarmed Circular 059/CD/550.20.001 of 5 June 2026 orders the immediate withdrawal of 53 FBeauty cosmetic products after a complaint-triggered inspection flagged four breaches of EU Regulation 1223/2009 — covering GMP, safety assessment, product information file and labelling.
Infarmed's 2025 monitor puts SNS medicine spending at a record €4,417M — +60% above the 2020 baseline. Hospitals carry €2,523M (+11.2%), ambulatory €1,894M (+12.4%), families €966M (+4.9%). Oncology adds €864.5M (+16%), orphan drugs +34.1%, and Q1 2026 hospitals already +7.6%.
